These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 19786678)

  • 1. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy.
    Weinberg JM; Appel LJ; Bakris G; Gassman JJ; Greene T; Kendrick CA; Wang X; Lash J; Lewis JA; Pogue V; Thornley-Brown D; Phillips RA;
    Arch Intern Med; 2009 Sep; 169(17):1587-94. PubMed ID: 19786678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
    Wright JT; Bakris G; Greene T; Agodoa LY; Appel LJ; Charleston J; Cheek D; Douglas-Baltimore JG; Gassman J; Glassock R; Hebert L; Jamerson K; Lewis J; Phillips RA; Toto RD; Middleton JP; Rostand SG;
    JAMA; 2002 Nov; 288(19):2421-31. PubMed ID: 12435255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic.
    Sarafidis PA; Blacklock R; Wood E; Rumjon A; Simmonds S; Fletcher-Rogers J; Ariyanayagam R; Al-Yassin A; Sharpe C; Vinen K
    Clin J Am Soc Nephrol; 2012 Aug; 7(8):1234-41. PubMed ID: 22595825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK).
    Gassman JJ; Greene T; Wright JT; Agodoa L; Bakris G; Beck GJ; Douglas J; Jamerson K; Lewis J; Kutner M; Randall OS; Wang SR
    J Am Soc Nephrol; 2003 Jul; 14(7 Suppl 2):S154-65. PubMed ID: 12819322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis.
    Maddirala S; Khan A; Vincent A; Lau K
    Am J Med Sci; 2008 Oct; 336(4):330-5. PubMed ID: 18854676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.
    Lea J; Greene T; Hebert L; Lipkowitz M; Massry S; Middleton J; Rostand SG; Miller E; Smith W; Bakris GL
    Arch Intern Med; 2005 Apr; 165(8):947-53. PubMed ID: 15851648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between beta-blockers and calcium channel blockers in patients with atrial fibrillation according to renal function.
    Parada Barcia JA; Raposeiras Roubin S; Fernández DG; García AG; Otero CI; González Bermúdez I; Íñiguez Romo A; Abu-Assi E
    Clin Cardiol; 2024 May; 47(5):e24257. PubMed ID: 38664980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial.
    Norris K; Bourgoigne J; Gassman J; Hebert L; Middleton J; Phillips RA; Randall O; Rostand S; Sherer S; Toto RD; Wright JT; Wang X; Greene T; Appel LJ; Lewis J;
    Am J Kidney Dis; 2006 Nov; 48(5):739-51. PubMed ID: 17059993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
    Agodoa LY; Appel L; Bakris GL; Beck G; Bourgoignie J; Briggs JP; Charleston J; Cheek D; Cleveland W; Douglas JG; Douglas M; Dowie D; Faulkner M; Gabriel A; Gassman J; Greene T; Hall Y; Hebert L; Hiremath L; Jamerson K; Johnson CJ; Kopple J; Kusek J; Lash J; Lea J; Lewis JB; Lipkowitz M; Massry S; Middleton J; Miller ER; Norris K; O'Connor D; Ojo A; Phillips RA; Pogue V; Rahman M; Randall OS; Rostand S; Schulman G; Smith W; Thornley-Brown D; Tisher CC; Toto RD; Wright JT; Xu S;
    JAMA; 2001 Jun; 285(21):2719-28. PubMed ID: 11386927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
    Esnault VL; Brown EA; Apetrei E; Bagon J; Calvo C; DeChatel R; Holdaas H; Krcmery S; Kobalava Z;
    Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
    Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
    Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N; Kalaitzidis R; Bakris GL
    Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic advantage of angiotensin-converting enzyme inhibitors in patients with proteinuric chronic kidney disease.
    Omae K; Ogawa T; Nitta K
    Heart Vessels; 2010 May; 25(3):203-8. PubMed ID: 20512447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
    Gluhovschi G; Mateş A; Gluhovschi C; Golea O; Gădălean F; Somai M; Ene I; Petrica L; Velciov S
    Rom J Intern Med; 2014; 52(1):30-8. PubMed ID: 25000676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive Medication Use in Older Patients Transitioning from Chronic Kidney Disease to End-Stage Renal Disease on Dialysis.
    Chang TI; Zheng Y; Montez-Rath ME; Winkelmayer WC
    Clin J Am Soc Nephrol; 2016 Aug; 11(8):1401-1412. PubMed ID: 27354656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
    Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study.
    Fu EL; Clase CM; Evans M; Lindholm B; Rotmans JI; Dekker FW; van Diepen M; Carrero JJ
    Am J Kidney Dis; 2021 May; 77(5):719-729.e1. PubMed ID: 33246024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.
    Huang RS; Cheng YM; Zeng XX; Kim S; Fu P
    Chin Med J (Engl); 2016 Mar; 129(5):562-9. PubMed ID: 26904991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.
    Pisoni R; Acelajado MC; Cartmill FR; Dudenbostel T; Dell'Italia LJ; Cofield SS; Oparil S; Calhoun DA
    J Hum Hypertens; 2012 Aug; 26(8):502-6. PubMed ID: 21677673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.